Zimmer Biomet Holdings, Inc. Files 10-Q for Period Ending March 31, 2024
Ticker: ZBH · Form: 10-Q · Filed: May 2, 2024 · CIK: 1136869
| Field | Detail |
|---|---|
| Company | Zimmer Biomet Holdings, INC. (ZBH) |
| Form Type | 10-Q |
| Filed Date | May 2, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: Zimmer Biomet, 10-Q, Financial Report, Medical Devices, Orthopedics
TL;DR
<b>Zimmer Biomet Holdings, Inc. has filed its quarterly report (10-Q) for the period ending March 31, 2024.</b>
AI Summary
ZIMMER BIOMET HOLDINGS, INC. (ZBH) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Zimmer Biomet Holdings, Inc. filed a 10-Q report for the period ending March 31, 2024. The filing was made on May 2, 2024. The company's principal executive offices are located at 345 East Main Street, Warsaw, Indiana. Zimmer Biomet Holdings, Inc. was formerly known as Zimmer Holdings Inc. until March 15, 2001. The company operates in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry.
Why It Matters
For investors and stakeholders tracking ZIMMER BIOMET HOLDINGS, INC., this filing contains several important signals. This 10-Q filing provides investors with the latest financial performance and operational updates for Zimmer Biomet Holdings, Inc. Understanding the details within this report is crucial for assessing the company's current financial health and future prospects in the medical device sector.
Risk Assessment
Risk Level: low — ZIMMER BIOMET HOLDINGS, INC. shows low risk based on this filing. The risk is low as this is a standard quarterly filing and does not appear to contain any immediate red flags or significant negative developments based on the provided header information.
Analyst Insight
Review the detailed financial statements and management discussion within the full 10-Q filing to understand Zimmer Biomet's performance and outlook.
Key Numbers
- 20240331 — Period End Date (CONFORMED PERIOD OF REPORT)
- 20240502 — Filing Date (FILED AS OF DATE)
- 1231 — Fiscal Year End (FISCAL YEAR END)
- 345 EAST MAIN STREET — Business Street (BUSINESS ADDRESS)
- WARSAW — Business City (BUSINESS ADDRESS)
- IN — Business State (BUSINESS ADDRESS)
- 46580 — Business Zip (BUSINESS ADDRESS)
- 5742676131 — Business Phone (BUSINESS PHONE)
Key Players & Entities
- ZIMMER BIOMET HOLDINGS, INC. (company) — FILER
- 0000950170-24-052097 (filing_id) — ACCESSION NUMBER
- 20240331 (date) — CONFORMED PERIOD OF REPORT
- 20240502 (date) — FILED AS OF DATE
- 0001136869 (company_id) — CENTRAL INDEX KEY
- 3842 (industry_code) — STANDARD INDUSTRIAL CLASSIFICATION
- DE (state) — STATE OF INCORPORATION
- ZIMMER HOLDINGS INC (company) — FORMER COMPANY
FAQ
When did ZIMMER BIOMET HOLDINGS, INC. file this 10-Q?
ZIMMER BIOMET HOLDINGS, INC. filed this Quarterly Report (10-Q) with the SEC on May 2, 2024.
What is a 10-Q filing?
A 10-Q is a quarterly financial report with unaudited financials, management discussion, and interim business updates. This particular 10-Q was filed by ZIMMER BIOMET HOLDINGS, INC. (ZBH).
Where can I read the original 10-Q filing from ZIMMER BIOMET HOLDINGS, INC.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ZIMMER BIOMET HOLDINGS, INC..
What are the key takeaways from ZIMMER BIOMET HOLDINGS, INC.'s 10-Q?
ZIMMER BIOMET HOLDINGS, INC. filed this 10-Q on May 2, 2024. Key takeaways: Zimmer Biomet Holdings, Inc. filed a 10-Q report for the period ending March 31, 2024.. The filing was made on May 2, 2024.. The company's principal executive offices are located at 345 East Main Street, Warsaw, Indiana..
Is ZIMMER BIOMET HOLDINGS, INC. a risky investment based on this filing?
Based on this 10-Q, ZIMMER BIOMET HOLDINGS, INC. presents a relatively low-risk profile. The risk is low as this is a standard quarterly filing and does not appear to contain any immediate red flags or significant negative developments based on the provided header information.
What should investors do after reading ZIMMER BIOMET HOLDINGS, INC.'s 10-Q?
Review the detailed financial statements and management discussion within the full 10-Q filing to understand Zimmer Biomet's performance and outlook. The overall sentiment from this filing is neutral.
How does ZIMMER BIOMET HOLDINGS, INC. compare to its industry peers?
Zimmer Biomet Holdings, Inc. operates in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry, a sector focused on developing and manufacturing devices for musculoskeletal health.
Are there regulatory concerns for ZIMMER BIOMET HOLDINGS, INC.?
The company is subject to regulatory oversight typical for medical device manufacturers, including standards for product safety and efficacy.
Industry Context
Zimmer Biomet Holdings, Inc. operates in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry, a sector focused on developing and manufacturing devices for musculoskeletal health.
Regulatory Implications
The company is subject to regulatory oversight typical for medical device manufacturers, including standards for product safety and efficacy.
What Investors Should Do
- Analyze the full 10-Q filing for detailed financial performance metrics.
- Investigate any specific operational or strategic updates mentioned in the report.
- Compare current quarter results with historical data and industry benchmarks.
Year-Over-Year Comparison
This is the initial filing provided for analysis, so a comparison to a previous filing is not possible with the given data.
Filing Stats: 4,409 words · 18 min read · ~15 pages · Grade level 7.8 · Accepted 2024-05-02 16:08:17
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value ZBH New York Stock Exchan
Filing Documents
- zbh-20240331.htm (10-Q) — 2269KB
- zbh-ex21.htm (EX-21) — 179KB
- zbh-ex31_1.htm (EX-31.1) — 12KB
- zbh-ex31_2.htm (EX-31.2) — 12KB
- zbh-ex32.htm (EX-32) — 8KB
- 0000950170-24-052097.txt ( ) — 11955KB
- zbh-20240331.xsd (EX-101.SCH) — 1720KB
- zbh-20240331_htm.xml (XML) — 2599KB
- Financial Information
Part I - Financial Information Item 1.
Financial Statements (unaudited)
Financial Statements (unaudited) 3 Condensed Consolidated Statements of Earnings for the Three Months Ended March 31, 2024 and 2023 3 Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2024 and 2023 4 Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 5 Condensed Consolidated Statements of Stockholders' Equity for the Three Months Ended March 31, 2024 and 2023 6 Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023 7 Notes to Interim Condensed Consolidated Financial Statements 8 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 33 Item 4.
Controls and Procedures
Controls and Procedures 33
- Other Information
Part II - Other Information Item 1.
Legal Proceedings
Legal Proceedings 34 Item 1A.
Risk Factors
Risk Factors 34 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 34 Item 3. Defaults Upon Senior Securities 34 Item 4. Mine Safety Disclosures 34 Item 5. Other Information 34 Item 6. Exhibits 36
– Financ ial Information
Part I – Financ ial Information
Financ ial Statements
Item 1. Financ ial Statements ZIMMER BIOMET HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (in millions, except per share amounts, unaudited) Three Months Ended March 31, 2024 2023 Net Sales $ 1,889.2 $ 1,831.0 Cost of products sold , excluding intangible asset amortization 512.3 500.8 Intangible asset amortization 142.1 133.4 Research and development 107.9 110.4 Selling, general and administrative 736.2 715.9 Restructuring and other cost reduction initiatives 124.4 41.8 Acquisition, integration, divestiture and related 0.4 1.3 Operating expenses 1,623.3 1,503.7 Operating Profit 265.9 327.3 Other (expense) income, net ( 0.1 ) 7.7 Interest expense, net ( 50.7 ) ( 48.2 ) Earnings before income taxes 215.1 286.8 Provision for income taxes 42.3 54.1 Net Earnings 172.8 232.8 Less: Net earnings attributable to noncontrolling interest 0.4 0.2 Net Earnings of Zimmer Biomet Holdings, Inc. $ 172.4 $ 232.5 Earnings Per Common Share Basic $ 0.84 $ 1.11 Diluted $ 0.84 $ 1.11 Weighted Average Common Shares Outstanding Basic 205.2 209.4 Diluted 206.2 210.4 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 ZIMMER BIOMET HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEM ENTS OF COMPREHENSIVE INCOME (in millions, unaudited) Three Months Ended March 31, 2024 2023 Net Earnings of Zimmer Biomet Holdings, Inc. $ 172.4 $ 232.5 Other Comprehensive Income (Loss): Foreign currency cumulative translation adjustments, net of tax ( 35.8 ) 12.4 Unrealized cash flow hedge gains, net of tax 34.7 8.8 Reclassification adjustments on hedges, net of tax ( 18.0 ) ( 19.0 ) Adjustments to prior service cost and unrecognized actuarial assumptions, net of tax ( 1.1 ) ( 0.9 ) Total Other Compre